|

Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure

RECRUITINGN/ASponsored by University Hospital, Montpellier
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Montpellier
Started2021-04-27
Est. completion2026-04-27
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04554277

Summary

Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. As a working hypothesis, we postulate that sST2 values monitoring could be an helpful guide for medical management in an attempt to reduce hospital readmission.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion criteria:

* 18 years or older
* Hospitalization for heart failure (NTproBNP(N-terminal pro-Brain Natriuretic Peptid) ≥450 pg/ml (ou BNP ≥400 pg/ml)

Exclusion criteria:

* Waiting for heart transplantation
* Scheduled valve surgery
* No fluent french
* Not able to provide informed consent
* Hemodynamic instability
* Poor outcome during the first week.
* Pregnancy
* Participating to other study

Conditions2

Heart DiseaseHeart Failure

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.